Johnson & Johnson (J&J) has announced promising results from a clinical study of a combination therapy for non-small cell lung cancer (NSCLC). The therapy, comprised of the antibody treatment Rybrevant and the experimental drug lazertinib, demonstrated increased duration of no progress in patients with a specific mutation in the EGFR protein.
The study focused on patients with a common EGFR mutation that leads to rapid cell growth and who had previously experienced disease progression after treatment with AstraZeneca's Tagrisso. Despite this prior treatment, J&J's combination therapy showed positive results, meeting the main goals of the study.
Rybrevant was initially approved in 2021 for a small subset of NSCLC patients, specifically those with a specific type of EGFR protein mutation, comprising only 2-3% of cases. However, this recent study suggests that the combination therapy could potentially benefit a larger population of NSCLC patients with the mutation.
J&J is also conducting a head-to-head study comparing its combination therapy with Tagrisso. The company expects to release data from this trial by the end of the year. If successful, J&J aims for its therapy to become a first-line treatment option for NSCLC patients with the mutation.
Tagrisso has been a significant revenue generator, generating over $5.4 billion in 2022. The potential success of J&J's combination therapy presents a promising alternative for patients, particularly those who have shown resistance or progression after treatment with Tagrisso.
This development brings hope to the NSCLC community, as it represents progress in the search for more effective treatment options and extends the duration of containment for this challenging cancer. Clinical advancements like these continue to drive the fight against lung cancer and improve the lives of patients around the world.